临床误诊误治2024，Vol.37Issue(11)：46-51,82,7.DOI:10.3969/j.issn.1002-3429.2024.11.009
恩格列净联合沙库巴曲缬沙坦治疗心房颤动合并射血分数保留的心力衰竭效果观察
Observation of the Effect of Empagliflozin Combined with Sacu-bitril/Valsartan on Atrial Fibrillation Complicated by Heart Fail-ure with Preserved Ejection Fraction
摘要
Abstract
Objective To explore the effect of Empagliflozin combined with sacubitril/valsartan on patients with atri-al fibril-lation(AF)and heart failure with preserved ejection fraction(HFpEF).Methods A total of 98 patients with atrial fi-brillation and HFpEF from July 2022 to July 2023 were selected and randomly divided into the research group(n=49)and the control group(n=49)using a random number table method.Both groups received conventional treatment,and on this basis,the control group was treated with sacubitril/valsartan and the research group was supplemented with Empagliflozin on the ba-sis of the control group.At 6 months after treatment,the effects were compared.The clinical efficacy of the two groups was compared,and the cardiopulmonary function[left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),maximum voluntary ventilation(MVV),forced expiratory volume in one second(FEV1),left ventricular remodeling index(LVRI)],inflammatory factors[interleukin-1β(IL-1β),lipoprotein-associated phospholipase A2(Lp-PLA2),sirtuin 1(SIRT1)],exercise tolerance[6-minute walk distance(6MWD)],quality of life[Minnesota Heart Failure Quality of Life Scale(MLHFQ)],serum microRNA(miR)-101a,miR-30a levels,and major adverse cardiovascular events(MACE)and adverse reac-tions during treatment in both groups were compared.Results The total clinical effective rate of the research group was 89.80%(44/49),which was higher than that of the control group[73.47%(36/49)](P<0.05).At 3 and 6 months after treat-ment,LVEDD,IL-1β,Lp-PLA2,MLHFQ score,and serum miR-30a in both groups were lower than those before treatment,while LVEF,MVV,FEV1,LVRI,SIRT1,6MWD,and serum miR-101a were higher than those before treatment(P<0.05).At 3 and 6 months after treatment,LVEDD,IL-1β,Lp-PLA2,MLHFQ score,and serum miR-30a in the research group were lower than those in the control group,while LVEF,MVV,FEV1,LVRI,SIRT1,6MWD,and serum miR-101a were higher than those in the control group(P<0.05).The incidence of MACE in the research group was lower than that in the control group(P<0.05);there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The efficacy of Empagliflozin combined with sacubitril/valsartan in the treatment of patients with AF and HFpEF is significant,which can reduce inflammatory response,improve patients'cardiopulmonary function,reduce the risk of MACE,enhance exercise tolerance,improve quality of life,and has high safety.关键词
心房颤动/心力衰竭/射血分数保留/恩格列净/沙库巴曲缬沙坦/左心室射血分数/白细胞介素-1β/运动耐力/生活质量Key words
Atrial fibrillation/Heart failure/Preserved ejection fraction/Empagliflozin/Sacubitril/valsartan/Left ventricular ejection fraction/Interleukin-1β/Exercise tolerance/Quality of life分类
临床医学引用本文复制引用
冯倩,师淼,赵东坡,刘学英..恩格列净联合沙库巴曲缬沙坦治疗心房颤动合并射血分数保留的心力衰竭效果观察[J].临床误诊误治,2024,37(11):46-51,82,7.基金项目
河北省卫生健康委员会医学科学研究项目(20211610) （20211610）
